The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    AbbVie’s $10.9 billion acquisition of Apogee Therapeutics is the year’s second-largest biotech buyout and the company’s biggest since its $63 billion takeover of Allergan in 2019.

    Updated June 22, 2026
  • Pharmacist explaining to patient
    Image attribution tooltip
    Permission granted by Walgreens
    Image attribution tooltip
    Sponsored by Walgreens

    The first 14 days: How specialty programs set patients up for success

    As specialty medicines play a growing role in healthcare, the patient journey that follows is equally critical.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends

    Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.

  • A sign for the FDA is displayed outside the agency's headquarters in Silver Spring, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection

    The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.

  • A woman's hands over her abdomen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Bionyra brings in $165M for next-generation immune drugs

    The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.

  • Medicine pill on 100 dollar banknote background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hospitals irate after Eli Lilly follows through on 340B ultimatum

    The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.

  • A Moderna logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Vaccines

    Moderna flu vaccine wins unanimous support from FDA panel

    The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.

  • Front sign of FDA building
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    UniQure to file gene therapy for approval, reflecting major shifts at FDA

    The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases. 

    FDA
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Biogen adds more immune drugs in $1B buyout of secretive startup RayThera

    The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues. 

  • Light micrograph of crypt architectural distortion in inflammatory bowel disease.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    cAMPfield lands $180M to build gut disease drug

    The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Pfizer CFO to step down; Denali sells a regulatory fast-pass

    A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.

  • The exterior of the Nasdaq MarketSite in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip
    IPO window

    Kardigan extends biotech’s streak of big IPOs with $400M haul

    Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.

  • Members of Vedana's executive team and board pose for a photo.
    Image attribution tooltip
    Permission granted by Vedana Therapeutics
    Image attribution tooltip
    Startup launches

    A new Westlake-backed biotech takes aim at migraines

    Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention. 

  • Colored scanning electron micrograph showing T lymphocytes, pre-T cells, and a granulocyte neutrophil.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Jazz zeroes in on next-gen T cell engagers with AbCellera deal

    The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of certain blood cancers.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    This year’s IPO class has already accounted for five of the six largest new biotech stock offerings since the start of 2022, according to BioPharma Dive data.

    Updated June 17, 2026
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Vaccines

    FDA staff scrutinizes evidence supporting Moderna’s flu vaccine

    Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA controversially refused to even review earlier this year. 

  • Employees working in the labs of Rapport Therapeutics, which recently began late-stage testing of a potentially first-of-its-kind seizure medication.
    Image attribution tooltip
    Permission granted by Rapport Therapeutics
    Image attribution tooltip
    Q&A

    Rapport ‘fully prepared’ to launch seizure drug solo, CEO says

    In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.

  • A flag flies above the headquarters campus of Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Pain drugs

    Lilly buys non-opioid pain drugmaker 4E

    It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.

  • 3D render using close-up of heart model covered with white, red, yellow pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Edgewise heart drug passes key trial test

    Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.

  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J multiple myeloma drug gains edge in earlier stage disease

    The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Neumora depression drug fails; EnGene to cut 50% of staff

    Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

  • Tennessee remittances tax government revenue payments
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Express Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies

    Express Scripts and the PBM lobby are following in CVS Caremark’s footsteps in filing complaints challenging the FAIR Rx Act, which was passed earlier this year despite vehement opposition from PBMs.

  • A piece of paper with the word "Medicare" emblazoned on a blue background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Medicare drug price rule may target under-the-skin Keytruda and Opdivo

    For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

  • china flag pill
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Amid a flurry of biotech deals, China looks to keep innovation at home

    The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies.

  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lilly scores early positive data for new JAK drug

    Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Parabilis sets a record with a $670M biotech IPO

    The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.